A breakthrough discovery by Nara Institute of Science and Technology researchers identifies EPHA2 as a critical surface protein for preserving stem cell potency. This finding holds promise for safer regenerative medicine by reducing the risk of tumorigenesis, paving the way for organ repair and treatment of degenerative conditions.
Researchers identified ephrin ligands in saliva samples of patients hospitalized with COVID-19, strongly associated with severe diagnosis. Saliva analysis could provide a simple, non-invasive method to detect infections and guide care.
Researchers discovered that cells can pack and release ephrins and Eph receptors through extracellular vesicles, allowing them to transmit signals over a distance. This discovery has significant implications for understanding cell communication and developing new treatments for diseases such as cancer and neurodegenerative disorders.
Researchers found that Eph receptors must form groups of three or four to become active, with the ratio of multimers to inactive dimers determining repulsion strength. This understanding can guide cell migration and growth, shedding light on diseases related to guidance system breakdowns.
A new Eph receptor tyrosine kinase, EphA4, is overexpressed in gastric cancer and associated with depth of invasion, recurrence, and poor prognosis. The study also found that EphA4 forms a hetero receptor complex with FGFR1, potentiating FGFR-mediated downstream signal transduction.
Researchers found that ephrin subtype EphrinB activates the EphB receptor, triggering a chemical pathway that stimulates synaptojanin-1 enzyme, essential for cellular endocytosis. This process is crucial for neurotransmitter regulation and nerve cell function.
Neurons use Eph receptors and ephrin ligands to guide nerve fiber growth and form connections in the developing brain, a process called axon pathfinding. This research may ultimately lead to understanding how to coax nerves to regrow and regenerate.